

























Fig. 6**A**

Control	AIC	
		Untreated sample
		Fixed with Paraformaldehyde
		Treated with 2% SDS 90°C 5 min
		Treated with 2% SDS 4°C 12h
		Treated with 1% SDS 4°C 12h

B

Control	AIC	
		Untreated sample
		Treated with 1% Triton X-100
	 anti-BSA antibody	BSA treated with 1% Triton X-100
		Treated with 0.5% Triton X-100
		Treated with CellLytic MT
		CellLytic soluble fraction
		CellLytic soluble fraction treated with SDS